All terms
RegulatoryRegulated Pathways
Combination Product
Product comprised of two or more regulated components - e.g., drug-device, biologic-device.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
Per 21 CFR 3.2(e), a combination product is composed of two or more different types of medical products (drug, device, biologic) that are physically, chemically, or otherwise combined or co-packaged. What the regulation says
The FDA defines combination products in 21 CFR 3.2(e) and specifies streamlined current Good Manufacturing Practice (cGMP) requirements in 21 CFR Part 4, ensuring compliance for products combining drugs, devices, and/or biological products. The EU MDR (Regulation (EU) 2017/745) also addresses products incorporating medical devices and medicinal substances, often requiring consultation with a medicines authority for classification and regulatory oversight.What this means in practice
FDA assigns a lead center based on the product's primary mode of action. Combination products must comply with both drug GMPs and device QSR/QMSR via streamlined cGMP requirements at 21 CFR Part 4.Examples
- A pre-filled syringe combining a drug and a delivery device is a common combination product.
- Drug-eluting stents, which release medication to prevent restenosis, are another example of a combination product.
- Insulin pens, which integrate a drug-delivery system with insulin, exemplify a drug-device combination.
Common pitfalls
- •Failing to identify a product as a combination product early in development can lead to significant regulatory delays.
- •Incorrectly determining the primary mode of action may result in submission to the wrong lead center, causing rework.
- •Assuming that only one set of GMPs applies can result in non-compliance with applicable regulations for both components.
- •Overlooking the need for a comprehensive quality management system that integrates requirements for all constituent parts is a common pitfall.
- •Underestimating the complexity of post-market surveillance and reporting for combination products can lead to compliance issues.
Frequently asked questions
The PMOA is the single mode of action of a combination product that provides the most important therapeutic action of the combination product. This determination guides which FDA center has primary jurisdiction for premarket review.
Related terms
Shared paths + categoryRegulatory
Request for Designation(RFD)
Formal mechanism to obtain a binding FDA decision on which Center will regulate a product.
Same category
Quality & Risk
Quality Management System Regulation(QMSR)
FDA's harmonized successor to the QSR, incorporating ISO 13485:2016 by reference.
Quality & Risk
Quality System Regulation(QSR / 21 CFR 820)
FDA's current good manufacturing practice (cGMP) requirements for medical devices.
Regulatory
Premarket Approval(PMA)
FDA's most stringent device marketing application, required for high-risk Class III devices.
De Novo & Breakthrough Pathways · adjacent
Regulatory
510(k) Premarket Notification(510(k))
FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.
De Novo & Breakthrough Pathways
Regulatory
Breakthrough Device Designation(BDD)
FDA program providing expedited review for devices that treat life-threatening or irreversibly debilitating conditions.
De Novo & Breakthrough Pathways
Latest in MedTech
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
FDA·1eCFR·1European Commission·1
- 1Combination ProductsVerifiedFDAfda.gov
- 221 CFR Part 4VerifiedeCFRecfr.gov
- 3European Commission - Medical DevicesVerifiedEuropean Commissionhealth.ec.europa.eu
Inline markers like [1] jump to the matching reference above.